

Table of Contents

Chapter 1 General Introduction.....	7
1.1 Diagnostic Tools	7
1.2Advantages of urine as a biological sample	11
1.3 Biological information in urine samples	13
1.3.1 Urine metabolites originated by exposure to toxic substances	15
1.3.2 Disease-related enzymes in urine.....	17
1.4 Methods for detecting diseases and toxic substances in urine samples.....	20
1.5 Nanotechnology and nanomedicine	24
1.6 Mesoporous silica materials in advanced applications	25
1.6.1 Synthesis of mesoporous silica nanoparticles.....	27
1.6.2 Functionalization of mesoporous silica materials	28
1.7 Molecular probes	30
1.8 Activable fluorescente probes.....	35
1.8.1 Molecular probes for detection of overexpressed enzymes	36
1.8.1.1 Molecular probes for <i>in vivo</i> detection of enzymes.....	37
1.8.1.2 Molecular probes for enzyme detection through urine	39
1.9 Near-infrared zwitterionic fluorescent agents with potential applications for urine-based disease detection	44
Chapter 2 Objectives.....	49
Chapter 3 A nanoprobe based on gated mesoporous silica nanoparticles for the selective and sensitive detection of benzene metabolite <i>t,t</i>-muconic acid in urine.	52
3.1 ABSTRACT	55
3.2 INTRODUCCION.....	56
3.3 RESULTS AND DISCUSSION.....	57

Table of Contents

3.4 CONCLUSION	64
3.5 REFERENCES.....	65
3.6 SUPPORTING INFORMATION.....	69
Chapter 4 NIR fluorescent probe for the detection of renal damage based on overrepresentation of alanine aminopeptidase enzyme.	82
4.1 ABSTRACT	85
4.2 INTRODUCTION.....	86
4.3RESULTS AND DISCUSSION.....	88
4.4 CONCLUSIONS.....	95
4.4 REFERENCES.....	96
4.5 SUPPORTING INFORMATION.....	98
Chapter 5 Leucine aminopeptidase (LAP) activatable nile blue-based NIR fluorescent probe for cancer detection.....	111
5.1 ABSTRACT	114
5.2 INTRODUCTION.....	115
5.3 RESULTS AND DISCUSSION.....	118
5.4 CONCLUSIONS.....	125
5.5 EXPERIMENTAL SECTION.....	126
5.6 REFERENCES.....	132
5.7 SUPPORTING INFORMATION.....	136
Chapter 6 NIR fluorescent probe for detection of alanine aminopeptidase (APN) overrepresentation as a cancer biomarker.	147
6.1 ABSTRACT.....	150
6.2 INTRODUCTION	151
6.3 RESULTS AND DISCUSSION	154
6.4 CONCLUSIONS	162
6.5 EXPERIMENTAL SECTION.....	162
6.6 REFERENCES	166

Table of Contents

6.7 SUPPORTING INFORMATION	172
Chapter 7 A renal clearable probe for <i>in vivo</i> monoamine oxidase (MAO) detection.	178
.....	
 7.1 ABSTRACT.....	181
 7.2 INTRODUCTION	182
 7.3 RESULTS AND DISCUSSION	185
 7.4 CONCLUSIONS	195
 7.5 EXPERIMENTAL SECTION.....	196
 7.6 REFERENCES	201
 7.7 SUPPORTING INFORMATION	207
Chapter 8 Conclusions and Perspectives	221